Hyperphosphatemia Drugs Market
Drivers
Increasing launches and approval
of novel drugs in key regions are expected to fuel the global Hyperphosphatemia
Drugs Market growth in near future. For instance, in 2016, Astellas Pharma
Inc. received marketing approval for its Kiklin Granules 86.2%, indicated for
the treatment of hyperphosphatemia in patients with chronic kidney disease in
Japan. In 2015, Keryx Biopharmaceuticals, Inc. received approval from European
Commission for new drug Fexeric (R) (ferric citrate coordination complex),
indicated for the treatment of hyperphosphatemia in adults with chronic kidney
disease.
In 2014, Keryx
Biopharmaceuticals, Inc. received U.S. Food and Drug Administration (FDA)
approval for drug Ferric Citrate (formerly known as Zerenex), a new, oral
iron-based treatment for dialysis patients with hyperphosphatemia. In 2014,
Keryx Biopharmaceuticals, Inc. launched its new drug Auryxia (ferric citrate)
tablets. Auryxia is an absorbable iron-based phosphate binder indicated for the
treatment of hyperphosphatemia in chronic kidney disease
Strategic merger and acquisition
by key players in the market is also expected to create a lucrative environment
for the hyperphosphatemia drugs market growth. For instance, in 2013, OPKO
Health, Inc. acquired Canada-based Cytochroma Inc., with this strategic
acquisition OPKO Health, Inc. has expanded its portfolio with Cytochroma Inc.’s
Alpharen, a non-absorbed phosphate binder to treat hyperphosphatemia in
dialysis patients.
Hyperphosphatemia is a condition
caused due to high level of phosphate or phosphorous in the blood. Phosphate is
a chemical found in body and contain mineral called phosphorous. Phosphorus
mineral is very important for the development of teeth and bones and also convert
food into energy for body.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1976
Phosphate is mainly found in the
teeth, bones, inside the cells, and in very smaller amounts in the blood.
Kidney functions for the management of phosphate level in the body. However,
various complications/diseases results into impairment of kidney, which leads
to chronically high level of phosphate in blood.
Hyperphosphatemia is very common
in people with chronic kidney disease more often in people with end-stage
kidney disease. Some other possible causes of hyperphosphatemia includes
diabetic ketoacidosis, uncontrolled diabetes, high vitamin D levels, and low
parathyroid hormone levels.
Furthermore, risk of developing
hyperphosphatemia is very high in the people suffering from chronic kidney
disease. Hence, increasing prevalence of chronic kidney disease is expected to
increase the chances of hyperphosphatemia among population, which in turn is
expected to increase demand for hyperphosphatemia drugs and drive hyperphosphatemia
drugs market growth.
For instance, according to the
data published in National Chronic Kidney Disease Fact Sheet 2017, an estimated
30 million people or 15% of U.S. adults are suffering from chronic kidney
disease. Chronic kidney diseases were estimated to be more common in Women (16%)
as compared to men (13%).
Hyperphosphatemia Drugs Market
Regional Analysis
North America is expected to hold
a dominant position in global hyperphosphatemia drugs market and it is expected
to account for largest market size, due to presence of key players in region
and frequent research and development activities by them for development of
novel drugs for treatment of hyperphosphatemia.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/hyperphosphatemia-drugs-market-1976
For instance, in 2017, U.S.-based
Ardelyx, Inc. received positive results in Phase 3 clinical trial for new drug
Tenapanor. Tenapanor is a first-in-class, proprietary, oral, experimental
medication indicated for the treatment of hyperphosphatemia in patients with
end-stage renal disease.
Furthermore, Asia Pacific
hyperphosphatemia drugs market is expected to witness significant growth in
near future owing to increasing approval of novel hyperphosphatemia treatment
drug in key regions such as China, and Japan. For instance, in 2014, Japan
Tobacco Inc. and its subsidiary Torii Pharmaceutical Co., Ltd. received
manufacturing and marketing approval of Riona Tablets 250 mg from Japanese
Ministry of Health, Labor and Welfare. Riona tablet is indicated for treatment
of hyperphosphatemia, it is a new phosphate binder containing ferric citrate
hydrate as the active pharmaceutical ingredient.
Hyperphosphatemia Drugs Market
Key Players
Key players operating in global
hyperphosphatemia drugs market include: Keryx Biopharmaceuticals, Inc.,
Astellas Pharma Inc., Japan Tobacco Inc., Ardelyx, Inc., OPKO Health, Inc.,
BioLink Life Sciences, Inc., F Hoffmann-La Roche AG, Lupin Limited, Fresenius
Medical Care, and Vifor Pharma Group.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1976
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment